Nurix Therapeutics, Inc.

NRIX

$25.32

-1.94%

N/A-$0.50

Healthcare

Biotechnology

NASDAQ

Active Trading

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for ...

Historical Employee Count of NRIX

Current

317

Change

+10.84%

Minimum

242

Maximum

317

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Nov 30, 2025	317	10-K	Jan 28, 2026	View
Nov 30, 2024	286	10-K	Jan 28, 2025	View
Nov 30, 2023	284	10-K	Feb 15, 2024	View
Nov 30, 2022	297	10-K	Feb 9, 2023	View
Nov 30, 2021	242	10-K	Jan 28, 2022	View

Supply Chain of NRIX

Upstream / Downstream / Proxies

Upstream

Contract Manufacturing Organizations (Undisclosed Single-Source Providers)Contract Research Organizations (Undisclosed Oncology CROs)DNA-Encoded Library Reagent & Synthesis SuppliersSpecialty Chemical & Raw Material Suppliers

Downstream

Roche Holding AGSIX:ROGilead Sciences, Inc.NASDAQ:GILD Sanofi S.A.NASDAQ:SNY Pfizer Inc. (via Seagen acquisition)NYSE:PFEClinical Trial Sites & Investigators

Proxies

Arvinas, Inc.NASDAQ:ARVN Kymera Therapeutics, Inc.NASDAQ:KYMR C4 Therapeutics, Inc.NASDAQ:CCCC Monte Rosa Therapeutics, Inc.NASDAQ:GLUE

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer